{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:36:04Z","timestamp":1775162164662,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,3]],"date-time":"2026-12-03T00:00:00Z","timestamp":1796256000000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM143044"],"award-info":[{"award-number":["R35GM143044"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD032350"],"award-info":[{"award-number":["S10OD032350"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011082","name":"The University of North Carolina at Chapel Hill School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dmd.2025.100195","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:58:20Z","timestamp":1762012700000},"page":"100195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["N-acetyltransferase (NAT) 1 and NAT2 enzyme activities drive interindividual variability in sulfamethoxazole N-acetylation"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-8291","authenticated-orcid":false,"given":"Raeanne M.","family":"Lanphier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany D.","family":"Latham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda J.","family":"Gerringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8532-2733","authenticated-orcid":false,"given":"Tyler","family":"Interrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corbin D.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"De Buysscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1848-0121","authenticated-orcid":false,"given":"John K.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-9800","authenticated-orcid":false,"given":"Klarissa D.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100195_bib1","series-title":"Trimethoprim Sulfamethoxazole","author":"Kemnic","year":"2025"},{"issue":"3","key":"10.1016\/j.dmd.2025.100195_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury\u2014types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dmd.2025.100195_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.apha.2018.12.001","article-title":"Mechanisms of idiosyncratic drug-induced liver injury","volume":"85","author":"Uetrecht","year":"2019","journal-title":"Adv Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100195_bib4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/03602530600959615","article-title":"Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction","volume":"38","author":"Uetrecht","year":"2006","journal-title":"Drug Metab Rev"},{"issue":"4","key":"10.1016\/j.dmd.2025.100195_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/1547691X.2014.983660","article-title":"Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury","volume":"12","author":"Mak","year":"2015","journal-title":"J Immunotoxicol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100195_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpt.564","article-title":"Drug-induced liver injury: advances in mechanistic understanding that will inform risk management","volume":"101","author":"Mosedale","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100195_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2156-9-21","article-title":"Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history","volume":"9","author":"Sabbagh","year":"2008","journal-title":"BMC Genet"},{"issue":"7","key":"10.1016\/j.dmd.2025.100195_bib8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00228-018-2448-y","article-title":"N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians","volume":"74","author":"Aklillu","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100195_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0034-1375953","article-title":"Epidemiology and risk factors for idiosyncratic drug-induced liver injury","volume":"34","author":"Bj\u00f6rnsson","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.dmd.2025.100195_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/hep.23720","article-title":"Pharmacogenetics of drug-induced liver injury","volume":"52","author":"Russmann","year":"2010","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.dmd.2025.100195_bib11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.dmd.2025.100195_bib12","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/ajg.2017.215","article-title":"Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians","volume":"112","author":"Chalasani","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100195_bib13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/clpt.1992.57","article-title":"Sulfamethoxazole is metabolized to the hydroxylamine in humans","volume":"51","author":"Cribb","year":"1992","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2025.100195_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0090-9556(25)08652-0","article-title":"Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine","volume":"18","author":"Cribb","year":"1990","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2025.100195_bib15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0090-9556(25)08967-6","article-title":"Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity","volume":"19","author":"Cribb","year":"1991","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100195_bib16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/mol.62.3.628","article-title":"Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation","volume":"62","author":"Naisbitt","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100195_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","article-title":"Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity","volume":"105","author":"Shear","year":"1986","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.dmd.2025.100195_bib18","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1021\/acs.chemrestox.9b00282","article-title":"Definition of haptens derived from sulfamethoxazole: in vitro and in vivo","volume":"32","author":"Tailor","year":"2019","journal-title":"Chem Res Toxicol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100195_bib19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/tx900034r","article-title":"Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation","volume":"22","author":"Callan","year":"2009","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100195_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/00007691-198612000-00010","article-title":"Pharmacokinetics, metabolism, and renal excretion of sulfadimidine and its N4-acetyl and hydroxy metabolites in humans","volume":"8","author":"Vree","year":"1986","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.dmd.2025.100195_bib21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2125.1995.tb05721.x","article-title":"Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole","volume":"39","author":"van der Ven","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00044011-199509010-00008","article-title":"Pharmacokinetics of sulfamethoxazole with its hydroxy metabolites and N4-acetyl-, N1-glucuronide conjugates in healthy human volunteers","volume":"9","author":"Vree","year":"1995","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib23","first-page":"29","article-title":"Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms","volume":"9","author":"Hein","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.dmd.2025.100195_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00008571-200104000-00004","article-title":"Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms","volume":"11","author":"Fretland","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"6","key":"10.1016\/j.dmd.2025.100195_bib25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/0006-2952(93)90280-A","article-title":"Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism","volume":"45","author":"Cribb","year":"1993","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100195_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/FPC.0b013e3283498ee9","article-title":"Human N-acetyltransferase 1 \u221710 and \u221711 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity","volume":"21","author":"Wang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/dmd.111.041855","article-title":"Phenotype of the most common \u201cslow acetylator\u201d arylamine N-acetyltransferase 1 genetic variant (NAT1\u221714B) is substrate-dependent","volume":"40","author":"Millner","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"5-6","key":"10.1016\/j.dmd.2025.100195_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/10937400903158383","article-title":"Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity","volume":"12","author":"Walker","year":"2009","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.31258","article-title":"Human leukocyte antigen B\u221714:01 and B\u221735:01 are associated with trimethoprim-sulfamethoxazole induced liver injury","volume":"73","author":"Li","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/clpt.1991.3","article-title":"Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions","volume":"49","author":"Rieder","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2025.100195_bib31","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/sj.bjp.0707122","article-title":"Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopat\u00edas Asociadas a Medicamentos). Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)","volume":"150","author":"Pachkoria","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-199902000-00007","article-title":"The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation","volume":"9","author":"Gill","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.dmd.2025.100195_bib33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0090-9556(25)06552-3","article-title":"N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes","volume":"23","author":"Cribb","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100195_bib34","first-page":"65","article-title":"Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis","volume":"506-507","author":"Hein","year":"2002","journal-title":"Mutat Res"},{"issue":"12","key":"10.1016\/j.dmd.2025.100195_bib35","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1124\/dmd.108.021246","article-title":"Nonenzymatic formation of a novel hydroxylated sulfamethoxazole derivative in human liver microsomes: implications for bioanalysis of sulfamethoxazole metabolites","volume":"36","author":"Sanderson","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2025.100195_bib36","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.119.088823","article-title":"Interindividual variation in CYP3A activity influences lapatinib bioactivation","volume":"47","author":"Bissada","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100195_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1004010","article-title":"Impact of pregnancy related hormones on drug metabolizing enzyme and transport protein concentrations in human hepatocytes","volume":"13","author":"Fashe","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.xphs.2020.10.037","article-title":"Differential detergent fractionation of membrane protein from small samples of hepatocytes and liver tissue for quantitative proteomic analysis of drug metabolizing enzymes and transporters","volume":"110","author":"Qasem","year":"2021","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.dmd.2025.100195_bib39","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1021\/pr4004213","article-title":"Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS\/MS with selected reaction monitoring","volume":"12","author":"Fallon","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.dmd.2025.100195_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106590","article-title":"Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS\/MS in the sandwich cultured human hepatocyte model","volume":"98","author":"Khatri","year":"2019","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"D1","key":"10.1016\/j.dmd.2025.100195_bib55","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Perez-Riverol","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.dmd.2025.100195_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272129","article-title":"ClinPharmSeq: a targeted sequencing panel for clinical pharmacogenetics implementation","volume":"17","author":"Lee","year":"2022","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.dmd.2025.100195_bib42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/FPC.0000000000000350","article-title":"Functional expression of human arylamine N-acetyltransferase NAT1\u221710 and NAT1\u221711 alleles: a mini review","volume":"28","author":"Hein","year":"2018","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"10.1016\/j.dmd.2025.100195_bib43","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.3390\/ijms26083881","article-title":"NAT2 acetylation status predicts hepatotoxicity during antituberculosis therapy: cumulative risk analysis of a multiethnic cohort","volume":"26","author":"Schiuma","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2025.100195_bib44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41439-020-0101-7","article-title":"Haplotype-specific PCR for NAT2 diplotyping","volume":"7","author":"Wichukchinda","year":"2020","journal-title":"Hum Gen Var"},{"key":"10.1016\/j.dmd.2025.100195_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/DHPS.S347522","article-title":"Clinical manifestations and genetic influences in sulfonamide-induced hypersensitivity","volume":"14","author":"Asyraf","year":"2022","journal-title":"Drug Healthc Patient Saf"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/pgs.11.122","article-title":"Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes","volume":"13","author":"Hein","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.dmd.2025.100195_bib47","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1038\/s41598-020-64508-0","article-title":"Human arylamine N-acetyltransferase 2 genotype-dependent protein expression in cryopreserved human hepatocytes","volume":"10","author":"Salazar-Gonz\u00e1lez","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmd.2025.100195_bib48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.bcp.2018.08.034","article-title":"Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1","volume":"156","author":"Salazar-Gonz\u00e1lez","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2025.100195_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.797469","article-title":"Arylamine N-acetyltransferase 1 activity is regulated by the protein acetylation status","volume":"13","author":"Salazar-Gonz\u00e1lez","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100195_bib50","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/dmd.30.6.631","article-title":"Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively","volume":"30","author":"Wen","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2025.100195_bib51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/psp4.12170","article-title":"Database of optimized proteomic quantitative methods for human drug disposition-related proteins for applications in physiologically based pharmacokinetic modeling","volume":"6","author":"Vrana","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2025.100195_bib52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000062","article-title":"PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2","volume":"24","author":"McDonagh","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.dmd.2025.100195_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00008571-199508000-00011","article-title":"A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Wolkenstein","year":"1995","journal-title":"Pharmacogenetics"},{"issue":"8","key":"10.1016\/j.dmd.2025.100195_bib54","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/carcin\/14.8.1689","article-title":"Genotype\/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans","volume":"14","author":"Bell","year":"1993","journal-title":"Carcinogenesis"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:58:53Z","timestamp":1773921533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625095042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0090955625095042"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100195","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-acetyltransferase (NAT) 1 and NAT2 enzyme activities drive interindividual variability in sulfamethoxazole N-acetylation","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100195"}}